Your session is about to expire
← Back to Search
V116 Vaccine for Pneumococcal Disease (STRIDE-8 Trial)
STRIDE-8 Trial Summary
This trial studies the safety & tolerability of a vaccine to protect adults against pneumococcal diseases. It also evaluates how well the vaccine works.
STRIDE-8 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSTRIDE-8 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.STRIDE-8 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had a heart attack or stroke in the last 3 months.You are allergic to any ingredient in V116, PCV15, or PPSV23 vaccines, including diphtheria toxoid.I have a blood clotting disorder that prevents me from getting shots in my muscles.I haven't had a fever or taken antibiotics in the last 3 days.I have a history of chronic kidney issues or autoimmune kidney disease.I have a condition like diabetes, liver disease, COPD, asthma, heart or kidney disease.I have not received a blood transfusion or blood products in the last 6 months, nor will I receive them within 30 days after getting a study vaccine.My current treatment for my condition has been stable for over 3 months with no major changes expected.I have severe lung blood pressure or Eisenmenger syndrome.I am not able to have children, or I use birth control or practice long-term abstinence.I've been on steroids (20 mg or more daily) for 2 weeks and haven't stopped them 14 days before the study vaccine.I have had or will have a pneumococcal vaccine outside this study's protocol.I am scheduled for a major organ transplant or surgery during this study.I haven't had a live virus vaccine in the last 30 days and won't have one for 30 days after getting the study vaccine.I use oxygen at home regularly.I have had active hepatitis in the past.I am currently on medication that affects my immune system.I had a serious lung infection confirmed by a lab test in the last 3 years.I have a cancer that is getting worse or needed treatment in the last 3 years.I haven't had non-live vaccines 2 weeks before or plan to within 30 days after the study vaccine.You have a weakened immune system due to conditions like HIV, autoimmune disease, or a missing spleen.The doctors believe you may have less than one year to live.I have had diabetic ketoacidosis or two severe low blood sugar episodes recently.
- Group 1: V116
- Group 2: PCV15 + PPSV23
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To which demographic is this research study open?
"In order to be considered, potential participants must have pneumococcal disease and fall within the age bracket of 18-64. A total of 500 individuals are needed for this clinical experiment."
Does this research project restrict participation to individuals over 35 years old?
"Patients aged 18 to 64 are the only ones eligible for this clinical trial. For those younger or older, there are 11 and 12 respective studies available."
Has V116 been validated by the Food and Drug Administration?
"The safety of V116 has been rated a 3, as there is evidence confirming its efficacy and numerous rounds of data which support its security."
Is this research project currently accepting new participants?
"Affirmative. Clinicaltrials.gov has evidence that this medical experiment began recruitment on February 13th 2023 and is actively recruiting patients at the present time. In total, 500 individuals are needed across 8 distinct locations."
Are there multiple facilities administering this research endeavor in the region?
"Currently, this clinical trial is recruiting subjects from 8 separate sites. These locations include West Palm Beach, Ridgeland and Durham amongst others. To reduce the amount of travel required to participate it is suggested that you select a site in proximity to your own location."
What is the total sample size for this research project?
"In order to conduct this medical trial, 500 participants must be secured that meet the established inclusion criteria. Individuals can sign up through Triple O Research Institute in West Palm Beach and SKY Integrative Medical Center/SKYCRNG in Ridgeland."
What is the primary objective of this clinical experiment?
"This clinical trial will primarily focus on assessing the occurrence of vaccine-related serious adverse events (SAEs) over a period of 5 days. Secondary objectives include measuring serotype-specific GMFRs and percentage of participants that experience a ≥4-fold rise in immunoglobulin G (IgG) or OPA responses post vaccination with V116 and PCV15 + PPSV2 respectively."
Share this study with friends
Copy Link
Messenger